Clinic Roundup

• Protalix BioTherapeutics Inc., of Carmiel, Israel, received clearance from the FDA to begin trials of PRX-102, a candidate for Fabry disease. It plans to begin enrolling patients in a Phase I/II study in the fourth quarter. PRX-102 is designed to potentially be an improved version of currently marketed enzyme replacement therapies for Fabry.